News

HIV vaccine fails trial test in South Africa

on

HIV vaccine fails trial test in South Africa

HIV vaccine fails trial test in South Africa

HIV vaccine fails trial test in South Africa

The vaccine failed to provide sufficient protection against HIV in Sub-Saharan Africa to young women, who accounted for a large number of infections last year.

An experimental vaccine for the Human Immunodeficiency Virus (HIV) in Africa has been shut down after data showed the shots offered only limited protection against the virus, researchers announced on Tuesday.

The vaccine, made by Johnson & Johnson (J&J), failed to provide sufficient protection against HIV in sub-Saharan Africa to young women, who accounted for a large number of infections in 2020.

Although the vaccine was found to be safe with no serious side effects reported, J&J said the study will not continue based on the efficacy data, a report published in the New York Times noted.

“Although this is certainly not the study outcome for which we had hoped, we must apply the knowledge learned from the … trial and continue our efforts to find a vaccine that will be protective against HIV,” said Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

The study

The trial, called Imbokodo, tested an experimental vaccine in 2,600 young women deemed at high risk of H.I.V. infection in five sub-Saharan African countries. Women and girls accounted for almost two-thirds of new H.I.V. infections in the region last year.

The vaccine relied on an adenovirus called Ad26, modified to carry fragments of four H.I.V. subtypes into the body in hopes of provoking an immune response that might defend against infection.

Participants in the Imbokodo trial, which began in 2017, were given two initial shots and two boosters over the course of a year. Researchers tracked the numbers of new infections in the placebo and vaccine groups from the seventh month (one month after the third vaccination) through the 24th month.

Over two years, 63 of 1,109 participants who received the placebo were infected with H.I.V., compared with 51 of 1,079 participants who received the vaccine — giving the vaccine an efficacy rate of 25 per cent.

Mitchell Warren, executive director of AVAC, an advocacy group that lobbies for AIDS prevention and treatment, said the cancellation of the trial was a “reality check” amid excitement about new vaccine technologies.

“It’s a grand reminder that H.I.V. is a pathogen unlike any other in its complexity,” he said. “We know the platform worked, but what do we put in it? Because this virus is infecting the exact same immune system that we’re trying to boost with a vaccine.”

Earlier studies, including one carried out in Thailand, had indicated that the kind of antibodies this vaccine provoked might be sufficient to offer good protection from H.I.V. for at least an initial period of time.

But in South Africa, the higher rates of H.I.V. incidence means you need something much more potent,” Glenda Gray, the principal investigator of the trial and chair of the South African Medical Research Council said.

He said the kind of immune responses that were induced were just not enough to stop the high attack rates seen in Africa

“When the disappointing data showed a low efficacy rate, guidelines set up before the trial dictated it should be shut down.

“A vaccine that offered only 25 per cent protection risked giving women a false sense of security,” Mr Gray said.

The results from the study are the latest setback to efforts to develop a vaccine to prevent the virus, which had infected over 37 million people globally as of 2020.

 

 

 

HIV vaccine fails trial test in South Africa
Join Naijawide WhatsApp Group & Telegram Channel
WATCH:Can You Cheat On Your Partner For One Million Naira? | NW VOX POP

About James Odediran

Recommended for you

Leave a Reply

Your email address will not be published.